Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Mar;33(3):387–390. doi: 10.1128/aac.33.3.387

Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families.

A S Monto 1, S A Schwartz 1, J K Albrecht 1
PMCID: PMC171498  PMID: 2543280

Abstract

Past studies conducted in Australian and American families have demonstrated that alpha 2b interferon (IFN) is effective in preventing rhinovirus-associated illnesses in exposed family members. IFN had been used by intranasal application for 7 days after exposure (5 x 10(6) IU/day). We used the same approach but with only 5 days of spraying (5 x 10(6) IU on day 1 and 2.5 x 10(6) IU on each subsequent day). This amount has been effective in studies involving seasonal prophylaxis. During the study period, a total of 178 rhinoviruses were isolated from the 199 enrolled families in Tecumseh, Mich. There were 434 courses of IFN use and 434 courses of placebo use. Although rhinoviruses were less frequently isolated from those using IFN than those using the placebo, no differences favoring IFN treatment could be found in any of the symptomatic episodes. In fact, more episodes were observed in IFN recipients than in placebo recipients, although the differences were not statistically significant. Additionally, there was no evidence of modification of the severity of episodes of illness. It was concluded that prevention of rhinovirus illness episodes postexposure required a dosage of at least 5 x 10(6) IU of IFN-alpha 2b.

Full text

PDF
390

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dolin R., Reichman R. C., Madore H. P., Maynard R., Linton P. N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982 Sep 2;307(10):580–584. doi: 10.1056/NEJM198209023071002. [DOI] [PubMed] [Google Scholar]
  2. Douglas R. M., Albrecht J. K., Miles H. B., Moore B. W., Read R., Worswick D. A., Woodward A. J. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection. J Infect Dis. 1985 Apr;151(4):731–736. doi: 10.1093/infdis/151.4.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Douglas R. M., Moore B. W., Miles H. B., Davies L. M., Graham N. M., Ryan P., Worswick D. A., Albrecht J. K. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986 Jan 9;314(2):65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  4. Farr B. M., Gwaltney J. M., Jr, Adams K. F., Hayden F. G. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother. 1984 Jul;26(1):31–34. doi: 10.1128/aac.26.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hayden F. G., Albrecht J. K., Kaiser D. L., Gwaltney J. M., Jr Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 1986 Jan 9;314(2):71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  6. Hayden F. G., Gwaltney J. M., Jr Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983 Sep;148(3):543–550. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  7. Hayden F. G., Gwaltney J. M., Jr, Johns M. E. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections. Antiviral Res. 1985 Apr;5(2):111–116. doi: 10.1016/0166-3542(85)90037-3. [DOI] [PubMed] [Google Scholar]
  8. Herzog C., Berger R., Fernex M., Friesecke K., Havas L., Just M., Dubach U. C. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study. Antiviral Res. 1986 May;6(3):171–176. doi: 10.1016/0166-3542(86)90011-2. [DOI] [PubMed] [Google Scholar]
  9. Longini I. M., Jr, Monto A. S., Koopman J. S. Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza. Int J Epidemiol. 1984 Mar;13(1):99–106. doi: 10.1093/ije/13.1.99. [DOI] [PubMed] [Google Scholar]
  10. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  11. Monto A. S., Albrecht J. K., Schwartz S. A. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. Antimicrob Agents Chemother. 1988 Jan;32(1):47–50. doi: 10.1128/aac.32.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Monto A. S., Bryan E. R., Ohmit S. Rhinovirus infections in Tecumseh, Michigan: frequency of illness and number of serotypes. J Infect Dis. 1987 Jul;156(1):43–49. doi: 10.1093/infdis/156.1.43. [DOI] [PubMed] [Google Scholar]
  13. Monto A. S., Gunn R. A., Bandyk M. G., King C. L. Prevention of Russian influenza by amantadine. JAMA. 1979 Mar 9;241(10):1003–1007. [PubMed] [Google Scholar]
  14. Monto A. S., Shope T. C., Schwartz S. A., Albrecht J. K. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis. 1986 Jul;154(1):128–133. doi: 10.1093/infdis/154.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Samo T. C., Greenberg S. B., Couch R. B., Quarles J., Johnson P. E., Hook S., Harmon M. W. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis. 1983 Sep;148(3):535–542. doi: 10.1093/infdis/148.3.535. [DOI] [PubMed] [Google Scholar]
  16. Samo T. C., Greenberg S. B., Palmer J. M., Couch R. B., Harmon M. W., Johnson P. E. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis. 1984 Aug;150(2):181–188. doi: 10.1093/infdis/150.2.181. [DOI] [PubMed] [Google Scholar]
  17. Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES